BNTX
BioNTech SE
96.90$
-1.5%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 90.6% | 57.5% | -183.6% | 1,367.0% | -55.3% | -42.1% | -449.5% | 50.7% | 56.3% | 33.3% | -356.5% | 10.4% | 27.9% | |
| 4.6% | 5.7% | 22.2% | 41.7% | 3.9% | 14.8% | 24.6% | 22.2% | 9.6% | 18.2% | 102.7% | 256.2% | 26.6% | |
| 1.7% | 1.0% | 8.7% | 15.7% | 3.3% | 2.0% | 12.1% | 12.3% | 1.8% | 2.7% | 19.0% | 19.8% | 3.6% | |
| -3.4% | – | – | – | – | – | – | – | – | – | – | – | – | |
| 71.4% | -120.0% | 128.7% | 1,984.6% | -58.1% | -62.6% | -239.8% | 218.6% | 48.1% | -24.0% | 56.1% | 574.9% | 45.0% | |
| 16.9% | 19.7% | 79.2% | 118.0% | 7.3% | 8.4% | 355.9% | 217.8% | 2.9% | 6.8% | 48.1% | 52.8% | 8.3% | |
| -137.6% | -191.7% | -1,333.2% | -193.3% | -13.1% | 54.6% | 717.8% | -10.2% | -65.6% | -292.2% | 2,244.4% | -98.4% | -39.1% | |
| 0.0% | 0.0% | – | – | – | – | – | – | – | – | – | – | – | |
| -33.7% | 0.6% | 0.0% | 0.0% | 0.0% | 0.0% | – | 0.0% | – | – | – | -125.1% | – | |
| -1.0% | – | – | – | -0.6% | -0.6% | -7.5% | -5.1% | -0.8% | -1.4% | 22.0% | 19.6% | 0.9% | |
| -34.7% | -0.2% | -4.5% | -19.2% | -0.7% | -0.7% | -7.9% | -5.7% | -0.9% | -1.6% | 22.4% | -105.1% | -4.2% | |
| -74.9% | -95.0% | -1,700.2% | 1,108.4% | -30.5% | -53.2% | 488.7% | 403.8% | -12.9% | -269.4% | 1,764.4% | -261.0% | -29.3% | |
| 73.7% | 77.3% | -262.8% | 1,248.9% | -62.6% | -50.6% | -805.4% | 268.4% | 53.4% | 26.4% | -404.6% | -42.4% | 19.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.